and FDA staffing decisions at a Senate hearing. EU says Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation Catalent does not pose antitrust issues.

The growing incidence of genetic disorders and chronic illnesses, including cancer and rare inherited conditions, is fueling the demand for advanced therapies, highlighting the need for strong ...

“The agreement to acquire the three Catalent manufacturing sites ... Neurotech Pharma's cell therapy Encelto has become the first FDA-approved therapy for idiopathic macular telangiectasia ...

Novo Nordisk NVO shares have lost 21% in the past three months against the industry’s growth of 4.6%. The company has also ...

"The positive data from our MM120 Phase 2b study in GAD helped secure breakthrough therapy designation from the FDA and led to the expansion of our pipeline into MDD. In 2025, we are focused on ...

Acadia Pharmaceuticals Inc. and Saniona (OMX: SANION) today announced the successful completion of the two originally planned cohorts in their Phase 1 multiple-ascending-dose MAD study (EUCT: ...

Last year marked an increase in federal securities class action filings, with plaintiffs filing 225 cases in 2024, up from 215 in 2023. Life sciences companies remained popular targets, accounting ...

John Chiminski brings more than three decades of leadership in healthcare and pharma services. He served as CEO of Catalent from 2009 to 2015, then as Chair and CEO from 2016 through 2022, and as ...

Regulatory clearances and approvals continue as agencies work to disseminate literature, raise awareness, redouble research efforts, and improve the efficacy of clinical trials.

Pharmaceutical Technology® discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer with Mike Baird from Schlafender Hase.